enVVeno Medical (NASDAQ:NVNO – Get Free Report) was upgraded by investment analysts at Zacks Research to a “hold” rating in a research note issued on Tuesday,Zacks.com reports.
Several other equities research analysts also recently issued reports on the company. Weiss Ratings downgraded enVVeno Medical from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday, June 30th. LADENBURG THALM/SH SH upgraded enVVeno Medical from a “hold” rating to a “strong-buy” rating in a research note on Monday. One analyst has rated the stock with a Strong Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold”.
View Our Latest Stock Report on NVNO
enVVeno Medical Price Performance
enVVeno Medical (NASDAQ:NVNO – Get Free Report) last announced its earnings results on Thursday, May 7th. The company reported ($5.89) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($8.40) by $2.51. On average, equities analysts expect that enVVeno Medical will post -16.19 earnings per share for the current fiscal year.
Hedge Funds Weigh In On enVVeno Medical
A number of hedge funds have recently bought and sold shares of the company. CM Management LLC increased its holdings in enVVeno Medical by 108.3% in the fourth quarter. CM Management LLC now owns 1,250,000 shares of the company’s stock valued at $401,000 after buying an additional 650,000 shares during the last quarter. ACT Capital Management LLC bought a new position in enVVeno Medical during the 4th quarter worth approximately $37,000. Kingdon Capital Management L.L.C. grew its position in shares of enVVeno Medical by 58.2% in the 3rd quarter. Kingdon Capital Management L.L.C. now owns 1,359,261 shares of the company’s stock worth $1,232,000 after acquiring an additional 500,000 shares in the last quarter. Creative Planning acquired a new position in shares of enVVeno Medical in the 2nd quarter worth approximately $54,000. Finally, Perceptive Advisors LLC bought a new stake in shares of enVVeno Medical in the 2nd quarter valued at approximately $5,127,000. 34.71% of the stock is currently owned by institutional investors and hedge funds.
enVVeno Medical Company Profile
enVVeno Medical, Inc is a clinical‐stage medical device company focused on the development and commercialization of subcutaneous vascular access systems for patients requiring repeated or long‐term intravenous therapy. Through its proprietary Freedom® platform, the company aims to offer an implantable alternative to traditional peripherally inserted central catheters (PICCs) and external tunneled catheters, addressing complications such as infection risk, dislodgement and patient discomfort.
The company’s lead product candidate, the Freedom PICC System, consists of a low‐profile, subcutaneous port connected to a flexible catheter designed for peripheral insertion.
See Also
- Five stocks we like better than enVVeno Medical
- Scotiabank Sees a New Growth Story for Cloudflare
- A Market Panic Just Discounted the AI Highway’s Tollbooth
- Why Exxon Could Be the Market’s Next Big Comeback Stock
- The Market Just Got Shaken—These 3 ETFs May Come Out Stronger
Receive News & Ratings for enVVeno Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for enVVeno Medical and related companies with MarketBeat.com's FREE daily email newsletter.
